Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Erlotinib + Glesatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 47 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162).|
|Glesatinib||MGCD265||AXL Inhibitor 27 MET Inhibitor 51 RON Inhibitor 10 VEGFR Inhibitor (Pan) 32||Glesatinib (MGCD265) inhibits several tyrosine kinases including MET (type II inhibitor), MST1R (RON), and AXL, as well as VEGFR1-3, and TIE2, which may result in decreased tumor growth (PMID: 25806189, PMID: 26555154, PMID: 32306194).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Erlotinib + Glesatinib||Phase I||Actionable||In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination therapy demonstrated safety and preliminary clinical efficacy, resulted in partial response in 1 patient, and stable disease for 6 cycles or more in 16% (7/45) of patients with advanced solid tumors (J Clin Oncol 30, 2012 (suppl; abstr e13602)).||detail...|
|Unknown unknown||gastroesophageal junction adenocarcinoma||not applicable||Erlotinib + Glesatinib||Phase I||Actionable||In a Phase I trial, 38% (3/8) of patients with gastroesophageal cancer remained on study for approximately 12-26 cycles with Glesatinib (MGCD265) and Tarceva (erlotinib) combination therapy (J Clin Oncol 30, 2012 (suppl; abstr e13602)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT00975767||Phase Ib/II||Docetaxel + Glesatinib Erlotinib + Glesatinib||A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer||Terminated||USA||0|